<DOC>
	<DOCNO>NCT02218359</DOCNO>
	<brief_summary>To demonstrate safety efficacy adjunctive therapy Amikacin Fosfomycin Inhalation System ( AFIS ) versus aerosolize placebo mechanically ventilated patient Gram-negative / Gram-positive bacterial colonization .</brief_summary>
	<brief_title>Aerosolized Amikacin Fosfomycin Mechanically Ventilated Patients With Gram-negative / Gram-positive Bacterial Colonization</brief_title>
	<detailed_description>The primary purpose study demonstrate safety efficacy amikacin fosfomycin inhalation system ( AFIS ) . AFIS consist amikacin solution ( AMS ) fosfomycin solution ( FFS ) , deliver aerosol lung via Investigational eFlow AFIS Inline System ( AFIS Inline System ) tamper evident reservoir . Patients randomize receive 5 day treatment either AFIS placebo , follow patient receive open label AFIS five day . The primary efficacy endpoint change baseline tracheal aspirate Gram-negative and/or Gram-positive bacterial density end 5-day randomized course study drug .</detailed_description>
	<mesh_term>Pneumonia</mesh_term>
	<mesh_term>Pneumonia , Bacterial</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Amikacin</mesh_term>
	<mesh_term>Fosfomycin</mesh_term>
	<criteria>Males nonpregnant , nonlactating female , ≥ 18 year ≤ 80 year age Intubated mechanicallyventilated Presence Gramnegative and/or Grampositive organism ( ) culture respiratory secretion sample obtain within previous 7 day History hypersensitivity amikacin fosfomycin . Diagnosis pneumonia , define presence new progressive infiltrate ( ) chest radiograph ( within 7 day prior screen ) , determine treat physician Use systemic antibiotic efficacy likely respiratory tract pathogens time randomization Severe acute respiratory distress syndrome ( define PaO2/FiO2 ≤ 100 mmHg diffuse infiltrate Chest Xray ) Refractory septic shock ( severe sepsis plus unstable hypotension , spite adequate fluid resuscitation vasopressor ) Evidence significant renal impairment ( serum creatinine &gt; 4.0 mg/dL within 24 hour prior screen ) . If serum creatinine &gt; 2.0 mg/dL , site must capable perform continuous renal replacement therapy , clinically indicate . Patients serum creatinine &gt; 4.0 mg/dL treat continuous renal replacement therapy ( continuous venousvenous hemofiltration continuous venousvenous hemodialysis ) chronic hemodialysis eligible Evidence ototoxicity ( history hearing aid use prior current hospitalization ) Evidence hepatotoxicity ( alanine aminotransferase [ ALT ] aspartate aminotransferase [ AST ] &gt; 3X upper limit normal value within 24 hour prior screen ) Any follow condition interfere assessment interpretation diagnosis response therapy : chest trauma loss stability thoracic cage follow fracture sternum , rib , ; increase amount fluid lung cavity require chest tube drainage ; lung cancer within last 2 year ; lung abscess ( ) ; anatomical bronchial obstruction ; suspect atypical pneumonia ; chemical pneumonitis ( e.g. , inhalation injury ) ; cystic fibrosis ; congestive heart failure ( lead PaO2/FiO2 ratio ≤ 100 mmHg diffuse infiltrate Chest Xray ) Immunocompromised patient , include neutropenia NOT due current infection ( absolute neutrophil count &lt; 500/mm³ ) , leukemia , lymphoma , human immunodeficiency virus ( HIV ) infection CD4 count &lt; 200 cells/mm3 , splenectomy ; early posttransplantation , cytotoxic chemotherapy , highdose steroid ( e.g. , &gt; 40 mg prednisone equivalent [ &gt; 160 mg hydrocortisone , &gt; 32 mg methylprednisolone , &gt; 6 mg dexamethasone , &gt; 200 mg cortisone ] daily &gt; 2 week ) Positive urine and/or serum betahCG pregnancy test ( woman reproductive age ) Participating participate investigational interventional study ( drug device ) within last 30 day ( 5 time halflife previously administer investigational compound , whichever long ) prior study treatment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>Gram-negative pneumonia</keyword>
	<keyword>Aerosol antibiotic</keyword>
	<keyword>Mechanical ventilation</keyword>
	<keyword>Amikacin</keyword>
	<keyword>Fosfomycin</keyword>
	<keyword>Pneumonia , Bacterial</keyword>
	<keyword>Pneumonia</keyword>
	<keyword>Bacterial Infections</keyword>
	<keyword>Lung Diseases</keyword>
	<keyword>Respiratory Tract Diseases</keyword>
	<keyword>Respiratory Tract Infections</keyword>
	<keyword>Anti-Bacterial Agents</keyword>
	<keyword>Anti-Infective Agents</keyword>
	<keyword>Therapeutic Uses</keyword>
	<keyword>Pharmacologic Actions</keyword>
	<keyword>MRSA</keyword>
</DOC>